Introduction {#Sec1}
============

Diabetes mellitus (DM) and thyroid dysfunction (TD) are endocrinopathies that are commonly seen in routine practice, and they frequently coexist. A high prevalence of TD is seen among both type 1 (T1DM) and type 2 (T2DM) diabetes mellitus patients \[[@CR1], [@CR2]\]. Autoimmunity can explain the common linkage between T1DM and autoimmune thyroid diseases; however, the linkage between T2DM and TD is more complicated. This review summarizes current knowledge about coexistent T2DM and TD and discusses enhanced screening recommendations as well as clinical implications for the management of these two endocrinopathies. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Search Strategy {#Sec2}
===============

We used the following strategy to search PubMed database for relevant articles published over the past 10 years: ("thyroid dysfunction"\[All Fields\] AND ("hypothyroidism"\[MeSH Terms\] OR "hypothyroidism"\[All Fields\] OR "hypothyroid"\[All Fields\]) AND ("hyperthyroidism"\[MeSH Terms\] OR "hyperthyroidism"\[All Fields\] OR "hyperthyroid"\[All Fields\])) AND ("diabetes mellitus"\[MeSH Terms\] OR ("diabetes"\[All Fields\] AND "mellitus"\[All Fields\]) OR "diabetes mellitus"\[All Fields\] OR "diabetes"\[All Fields\] OR "diabetes insipidus"\[MeSH Terms\] OR ("diabetes"\[All Fields\] AND "insipidus"\[All Fields\]) OR "diabetes insipidus"\[All Fields\]) AND ("2009/02/14"\[PDat\]: "2019/02/11"\[PDat\]).

In addition, we searched the websites of major diabetes and endocrine practice professional organizations for recommended guidelines on thyroid screening in persons with T2DM and diabetes screening in TD.

Prevalence of Diabetes and Thyroid Dysfunction {#Sec3}
==============================================

Both T2DM and TD are chronic diseases that require lifelong treatment and have a long-lasting effect on cardiovascular health. According to the International Diabetes Federation (IDF), in the year 2017, approximately 425 million adults worldwide were living with diabetes \[[@CR3]\]. The total prevalence of diabetes is increasing and is expected to be 629 million by 2045 \[[@CR3]\].

As per a large European meta-analysis, TD is present in 3.82% of the general population \[[@CR4]\]. Its prevalence among those with T2DM is significantly higher, ranging from 9.9 to 48% \[[@CR5], [@CR6]\]. This wide range of prevalence can be explained by the use of different definitions for TD diagnosis, depending on the presence of anti-thyroid peroxidase (anti-TPO), antithyroglobulin antibody (anti-TG), or both. In many studies, most T2DM patients with TD had subclinical hypothyroidism (SCH), and several new cases of TD were diagnosed during clinical evaluations, highlighting the need for enhanced screening for TD in T2DM patients \[[@CR5], [@CR7], [@CR8]\]. Just as in the nondiabetic population, TD was found to be more common in females than in males with diabetes \[[@CR8]--[@CR10]\]. TD is more common in T1DM than in T2DM patients, but the pathophysiology is more complex in T2DM patients and has greater clinical implications.

Clinical Guidelines on Screening for Thyroid Disorders in Diabetes {#Sec4}
==================================================================

It is important to screen for TD in T2DM patients as each of these endocrinopathies and their complex interdependent interactions increase cardiovascular risks. However, some guidelines do not mention anything about monitoring thyroid function in T2DM \[[@CR11]--[@CR13]\], while others recommend a thyroid function test at baseline but are against routine annual thyroid screening in T2DM \[[@CR14]\] (Table [1](#Tab1){ref-type="table"}).Table 1Major recommendations for thyroid screening in diabetes mellitus patientsGuidelinesScreening recommendations in diabetesComments2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum \[[@CR11]\]In high-risk women, serum TSH to be tested at baseline; reflex anti-TPO if TSH is 2.5--10 mU/LT1DM considered high risk. No specific comments about T2DM2012 Clinical Practice Guidelines for Hypothyroidism in Adults: cosponsored by The American Association of Clinical Endocrinologists and The American Thyroid Association \[[@CR15]\]Thyroid palpation and serum TSH measurement at baseline and at regular intervals in T1DM patients, especially if goitre or autoimmune disease presentNo specific comments about T2DM2006 UK Guidelines for the Use of Thyroid Function Tests by the British Thyroid Association and the Association of Clinical Biochemistry Guidelines \[[@CR14]\]TFT at baseline and annually for T1DM. In T1DM, TSH, FT4, and anti-TPO measured preconception, at booking, and at 3 months postpartum. TFT at baseline for T2DMAnnual tests not recommended for T2DM2015 NICE Guideline for Type 2 Diabetes in Adults: Management \[[@CR12]\]No mention of monitoring thyroid function in T2DMStandards of Medical Care in Diabetes---2017 by the American Diabetes Association \[[@CR13]\]Thyroid palpation at presentation. At T1DM diagnosis, tests recommended for anti-TPO, anti-TG, and TSH. Frequent rechecking if symptoms suggest TDNo mention of monitoring thyroid function in T2DM or GDMItalian Association of Clinical Endocrinologists and Italian Association of Clinical Diabetologists Position Statement: Diabetes Mellitus and Thyroid Disorders: Recommendations for Clinical Practice \[[@CR16]\]TFT at baseline and annually for T1DM patientsTFT during DKA with careful evaluationRe-evaluation of newly detected hyperglycaemia in hyperthyroid subjectsSerum TSH assay in case of repeated hypoglycaemiaIn diabetic patients with SCH, TSH check every 6 monthsRoutine ultrasound screening of thyroid gland at T2DM diagnosis is not suggested*T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus, *GDM* gestational diabetes, *TD* thyroid disorders, *TSH* thyroid-stimulating hormone, *anti-TPO* anti-thyroid peroxidase antibody, *anti-TG* antithyroglobulin antibody, *FT4* free thyroxine, *TFT* thyroid function test, *NICE* National Institute for Clinical Excellence, *SCH* subclinical hypothyroidism, *OGTT* oral glucose tolerance test

In its guidance for 2000, the American Thyroid Association recommended that adults who were at least 35 years old should be screened for thyroid disorders by measuring serum thyrotropin every 5 years irrespective of whether they were diabetic or nondiabetic \[[@CR17]\]. However, the 2015 Thyroid Dysfunction: Screening Guidelines of the US Preventive Services Task Force conclude that there is insufficient evidence to recommend TD screening in nonpregnant or asymptomatic adults \[[@CR18]\].

The recommendations for thyroid function screening of T2DM patients are not clear. The increasing evidence supporting a link between T2DM and TD, however, suggests that screening may need to be considered \[[@CR19]\].

Clinical Implications of Diabetes and Thyroid Disease Coexistence {#Sec5}
=================================================================

Both insulin and thyroid hormone are affected by autoimmune pathology, are part of metabolic syndrome, and affect the cellular metabolism. The pathophysiological association between T2DM and TD is believed to be the result of interplay between various biochemical, genetic, and hormonal malfunctions \[[@CR20]\]. Increased expression of the hepatic glucose transporter type 2 gene (GLUT2) is found in hyperthyroidism \[[@CR20]\]. Intracellular triiodothyronine (T3) may also play a role in insulin sensitivity \[[@CR21]\]. It mediates the action of the GLUT4 gene in skeletal muscles and increases basal and insulin-mediated glucose transport \[[@CR20]\]. Homozygosity for the Thr92Ala polymorphism of the deiodinase type 2 (DIO2) gene also enhances the risk for T2DM \[[@CR20]\].

T2DM and TD have similar signs and symptoms, such as oedema, fatigue, pallor, and weight gain. Thus, T2DM can mask TD and TD can mask early diabetic complications. Antidiabetic therapy may affect thyroid function, and antithyroid drugs can worsen glycaemic control. Hence, dose adjustments may be needed during clinical practice.

Thyroid Hormones and Glucose Homeostasis {#Sec6}
----------------------------------------

Excess circulating thyroid hormones in hyperthyroidism is associated with poor glycaemic control, including hyperglycaemia and insulinopenia. When normal individuals develop hyperthyroidism, nearly 2--3% of them develop overt diabetes \[[@CR21]\]. Nearly 50% of those with Graves' disease have some degree of glucose intolerance \[[@CR21]\]. Diabetic patients with hyperthyroidism experience worsened glycaemic control. Thyrotoxicosis can precipitate diabetic complications such as diabetic ketoacidosis \[[@CR22]\] and endothelial dysfunction \[[@CR23]\]. Endothelial dysfunction increases the risk of cardiovascular comorbidities.

Thyroid hormone can act on various organs to affect glucose metabolism (Table [2](#Tab2){ref-type="table"}). It increases gastrointestinal motility and enhances glucose absorption \[[@CR24]\]. In the liver, it increases the activity of phosphoenolpyruvate carboxykinase (PEPCK), an enzyme that enhances gluconeogenesis \[[@CR24]\]. This hepatic gluconeogenesis may occur through the direct effect of the thyroid hormone or indirectly via glucagon or catecholamine \[[@CR20], [@CR24]\].Table 2Effect of thyroid hormone on glucose metabolism in different organs or cellsOrgan/cellsEffect on glucose metabolismGastrointestinal tractIncreased glucose absorptionLiverIncreased hepatic gluconeogenesisAdipose tissueIncreased lipolysis; increased serum free fatty acidSkeletal muscleIncreased glucose uptakePancreatic beta cellsIncreased insulin secretionPancreatic alpha cellsIncreased glucagon secretion

The enhanced glycogenolysis and increased hepatic glucose output induces hyperinsulinaemia and glucose intolerance, causing peripheral insulin resistance \[[@CR20]\]. This worsens subclinical diabetes and exaggerates the hyperglycaemia in T2DM, increasing the risk of diabetic complications.

In the adipose tissues, thyroid hormone increases lipolysis. The increased serum free fatty acid level causes insulin resistance \[[@CR24]\]. Elevated lipolysis and increased hepatic β-oxidation, complicated by an insulin-deficient state, can lead to ketoacidosis \[[@CR20], [@CR24]\].

Hyperthyroidism increases GLUT4 gene expression and glucose uptake in skeletal muscles \[[@CR24]\]. Thyroid hormones also directly control insulin secretion by beta cells. Hypothyroidism reduces glucose-induced insulin secretion, whereas hyperthyroidism enhances the response of beta cells to glucose. Degradation of insulin is also increased by thyroid hormone, and thyrotoxicosis increases insulin clearance \[[@CR20], [@CR24]\]. Thyroid hormone also increases glucagon secretion by pancreatic alpha cells \[[@CR24]\].

Effects of Diabetes on Thyroid Disorders {#Sec7}
----------------------------------------

Diabetes affects thyroid function by altering the thyroid-stimulating hormone (TSH) level and impairing the conversion of thyroxine (T4) to triiodothyronine (T3) in the peripheral tissues \[[@CR21], [@CR25]\]. In euthyroid DM patients, the nocturnal TSH peak is absent or reduced and the TSH response to thyrotropin-releasing hormone (TRH) is also impaired. Hyperglycaemia of longer duration can have a cumulative effect on TD \[[@CR25]\]. While interpreting thyroid function tests, it is important to consider that, like other acute systemic illnesses, diabetic ketoacidosis can decrease T3 and T4 levels while TSH levels remain normal \[[@CR26]\]. Insulin resistance and hyperinsulinaemia lead to proliferation of thyroid tissues, an increased incidence of nodular thyroid disease, and a larger goitre \[[@CR21], [@CR27]\].

In hypothyroid patients with coexisting diabetes, the efficacy of thyroid hormone treatment may be affected \[[@CR21]\]. T1DM is more common in patients with Graves' orbitopathy (GO) than in the normal population \[[@CR21]\]; GO is more frequent and severe in Graves' disease patients with T2DM and is significantly associated with duration, obesity, and vasculopathy \[[@CR28]\]. Diabetic patients with GO also have a higher incidence of dysthyroid optic neuropathy than nondiabetics \[[@CR21]\].

Diabetes Mellitus, Thyroid Dysfunction, and Pregnancy {#Sec8}
-----------------------------------------------------

Maternal and foetal health can be affected by both DM and TD. A significantly higher prevalence of hypothyroxinaemia is found in women with gestational DM (GDM) \[[@CR21], [@CR29]\]. Also, the titre of anti-TPO is higher in pregnant women with T1DM \[[@CR21]\]. Hypothyroidism can complicate the pregnancy and cause pregnancy-induced hypertension, preeclampsia, abruptio placentae, postpartum haemorrhage, impaired neurodevelopment of the infant, preterm delivery, and low birth weight \[[@CR30], [@CR31]\]. Children born to hypothyroid mothers or to those with GDM have impaired neuropsychological development \[[@CR32], [@CR33]\].

Postpartum TD occurs in up to one-quarter of women with T1DM \[[@CR21]\]. Though thyroid antibodies may not increase GDM risk in pregnant euthyroid women, overt hypothyroidism during pregnancy increases the risk of developing diabetes later in life \[[@CR34], [@CR35]\]. Women with a history of GDM also have an increased risk of developing postpartum thyroiditis \[[@CR36]\].

Subclinical Hypo- or Hyperthyroidism in Diabetes {#Sec9}
------------------------------------------------

In several studies, SCH accounts for a large proportion of the TD encountered in diabetes patients \[[@CR7], [@CR37]--[@CR40]\]. Subclinical hyperthyroidism has also been reported in such patients, although less commonly than SCH \[[@CR38], [@CR39]\].

The clinical implications of subclinical hypo- or hyperthyroidism in DM will depend on the probability of progression to overt diabetes, metabolic control of diabetes, and the potential for benefits with thyroid hormone treatment \[[@CR21]\]. SCH causes hypertension and hyperlipidaemia, affects insulin secretion, impairs both micro- and macrovascular function, and thereby increases the risk of diabetic nephropathy, retinopathy, peripheral arterial disease, and peripheral neuropathy \[[@CR41]--[@CR43]\]. SCH may, however, have a protective effect on noncardiovascular mortality in T2DM \[[@CR44]\].

Thyroid Nodules and Carcinoma in Diabetes {#Sec10}
-----------------------------------------

The association between T2DM and the incidence of thyroid cancer is a topic of debate. A large prospective cohort study found an increased incidence of differentiated thyroid cancer among diabetic women \[[@CR45]\]. The risk was not elevated in men. Another large prospective study \[[@CR46]\] as well as a pooled analysis of several prospective studies \[[@CR47]\] found no significant association between diabetes and thyroid cancer. A previous literature review had suggested that any association between T2DM and thyroid cancer was probably weak \[[@CR48]\]. More recent meta-analyses have found a 1.38-fold-increased risk for thyroid cancer in women with pre-existing diabetes \[[@CR49]\] and a 20% increase in thyroid cancer in DM patients \[[@CR50]\] compared to their nondiabetic counterparts. In a Korean study, however, early T2DM patients had a low incidence of thyroid cancer, with the effect lasting up to 6 years after the T2DM was first diagnosed \[[@CR51]\]. A retrospective study published in December 2018 found a significantly higher risk of thyroid cancer among Chinese women with T2DM \[[@CR52]\].

Glycated Albumin Levels {#Sec11}
-----------------------

Glycated albumin, like glycated haemoglobin, is used as an indicator for glycaemic control in diabetes. It is affected by both glucose metabolism and albumin metabolism. Thyroid hormone promotes albumin catabolism, so the glycated albumin level may also be altered by TD \[[@CR24]\]. Careful assessment of the glycated albumin in diabetics with TD is needed.

Seaweed in the Diet {#Sec12}
-------------------

Seaweed is a common ingredient of Asian cuisine. Its use is highly recommended in the diets of those with diabetes, as it is low in calories and high in fibre, and has a high mineral content. However, seaweed has a high iodine content and can precipitate TD in susceptible patients \[[@CR24]\].

Effect of Drugs on Thyroid Function and Glycaemic Control {#Sec13}
---------------------------------------------------------

Drugs administered for diabetes, TD, and other comorbidities can alter thyroid function or glycaemic control in persons with coexisting T2DM and TD (Table [3](#Tab3){ref-type="table"}). Dose adjustments or a change in treatment regimen may be required.Table 3Effects of various drugs in coexistent diabetes and thyroid disordersDrugsEffects of anti-diabetic drugs on thyroid function in patients with T2DMBiguanides (metformin) \[[@CR53], [@CR54]\]Reduces TSH levelReduces risk of thyroid cancerReduces thyroid volume and nodule sizeMay be a promising therapy for patients with TDSulfonylureas \[[@CR55]\]Increases the risk of thyroid cancerIncreases risk of hypothyroidism and goitreThiazolidinediones \[[@CR24], [@CR56]\]Inhibits the activity of thyroid hormone receptorsIncreases TSHIncreases IGF-1Decreases FT4Aggravates thyroid-associated orbitopathyDrugsEffects of anti-thyroid drugs on glycaemic controlMethimazole \[[@CR24]\]Is related to the development of insulin autoimmune syndromeMay cause hypoglycaemia in patients with diabetesCarbimazole \[[@CR57]\]Insulin autoimmune syndrome has been reportedLevothyroxine \[[@CR58]\]Reduces fasting and postprandial glucose levelsReduces the glycosylated haemoglobin level*T2DM* type 2 diabetes mellitus, *TSH* thyroid-stimulating hormone, *TD* thyroid disorder, *IGF1* insulin-like growth factor-1, *FT4* free thyroxine

There are also reports of increased incidence of thyroid cancer with antidiabetic drugs such as incretin mimetics and insulin analogues. However, the evidence is not strong enough to discourage the use of these antidiabetic medications \[[@CR59], [@CR60]\].

Role of Thyroid Hormone Analogues {#Sec14}
---------------------------------

Thyroid hormones affect the metabolism of lipids, proteins, and carbohydrates. Strategies are being explored for the use of thyroid hormone analogues in the management of diabetes, obesity, and atherosclerosis \[[@CR24], [@CR61]\]. Researchers are searching for potent thyromimetics that can exert the desired therapeutic effects without producing the harmful effects of thyroid hormones.

Simplified Screening Strategy {#Sec15}
=============================

Although current guidelines on the annual screening of T2DM patients for TD are not consistent, there is no doubt that patients with diabetes are at increased risk for thyroid disorders. Unrecognized TD can worsen glycaemic control and increase the cardiovascular risk in T2DM. Kadiyala et al. recommend that all patients of diabetes should be screened for TSH and anti-TPO at baseline \[[@CR62]\]. In euthyroid T1DM, annual TSH screening is required for all patients. In euthyroid T2DM patients, an annual TSH test is only needed in those with TSH ≥ 2.0 mU/L or detectable anti-TPO. In others, a TSH test is recommended every 3--5 years (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Simplified algorithm for thyroid screening in diabetes (modified from Kadiyala et al. \[[@CR62]\]). *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes melliltus, *TSH* thyroid-stimulating hormone, *anti-TPO* thyroid peroxidase antibody

Conclusion {#Sec16}
==========

An increased prevalence of TD is being seen among patients with T2DM. In many studies, thyroid function tests have revealed that a substantial proportion of the new T2DM patients with TD have subclinical hypothyroidism. International guidelines vary widely and do not specifically suggest routine screening for this milder form of TD in T2DM patients. Coexistent T2DM and TD pose a higher cardiovascular disease risk. Insulin resistance links these conditions. TD can worsen T2DM and diabetes can worsen thyroid function. Antidiabetic drugs can alter thyroid function, and antithyroid drugs can alter glycaemic control. Considering the clinical implications of the coexistence of T2DM and TD, a more systematic approach to thyroid testing in T2DM is needed. Regular monitoring of glycaemic control in thyroid dysfunction is also suggested. More research is warranted to study the relationship between T2DM and TD.
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